NAUT — Nautilus Biotechnology, Inc.

Nautilus Biotechnology Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Operating Expenses: $15.4 million, down 23% year-over-year.
• Fiscal Year 2025 Total Operating Expenses: $66.8 million, a decrease of 18% from 2024.
• R&D Expenses for FY 2025: $41.1 million, down 19% from $50.5 million in FY 2024.
• G&A Expenses for FY 2025: $25.7 million, down 17% from $31.0 million in FY 2024.
• Cash Position: $156.1 million in cash, cash equivalents, and investments.
• Cash Burn: $50.2 million in FY 2025, reduced from $57.8 million in FY 2024.
• 2026 Cash Burn Guidance: Expected to be between $65 million to $70 million, with operating expenses anticipated to grow by 15% to 20%.

2. Strategic Updates and Business Highlights

• Product Development: Nautilus introduced the Voyager instrument at the US HUPO Conference, receiving positive feedback from researchers.
• Early Access Program: Launched in January 2026, allowing partners to engage with the Tau proteoform assay, aimed at fostering biological discovery and aligning workflows with customer needs.
• Collaborations: Announced a $1.6 million collaboration with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to develop an alpha-synuclein proteoform assay for Parkinson's disease.
• Technical Progress: Significant advancements in assay configurations and the development of the proteoform assay portfolio, with the Tau assay on track for early access sample processing by the end of Q1 2026.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipating modest revenue from early access customers and grant funding, with a more significant revenue ramp expected in 2027 upon commercial launch.
• Commercial Launch Plans: Expected to begin in late 2026, with instrument preorders and installations starting in early 2027, including the Voyager instrument and proteoform assays.
• Market Expansion: Plans to introduce an oncology-focused proteoform assay by the second half of 2026, indicating potential growth in other therapeutic areas beyond neurodegeneration.

4. Bad News, Challenges, or Points of Concern

• Sales Capacity: Currently, Nautilus has no sales personnel, which may hinder immediate revenue generation and customer engagement efforts.
• Revenue Expectations: While some revenue is anticipated in 2026, the majority of the revenue ramp is pushed to 2027, which may not meet market expectations.
• Operational Risks: Continued reliance on collaborations for validation and insights may expose Nautilus to risks if partnerships do not yield expected results or if competitive pressures increase.

5. Notable Q&A Insights

• Technical Milestones: Management highlighted key technical achievements, including the readiness of the Tau proteoform assay and the Voyager instrument's performance, which have been positively received by early customers.
• Revenue Projections: Clarified that modest revenue is expected from early access and grant funding in 2026, with a target of approximately $0.5 million, emphasizing that significant revenue growth will occur in 2027.
• Customer Feedback: Positive feedback from early access customers regarding data quality and the instrument's capabilities was noted, indicating strong interest in the technology and its applications in research.

Overall, Nautilus Biotechnology demonstrated strong operational discipline in Q4 2025, with significant advancements in product development and strategic collaborations, while also setting the stage for future growth despite challenges related to sales capacity and revenue generation timelines.